Business
Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders
DUBLIN, Aug. 28, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new ampreloxetine
About this update from Theravance Biopharma, Inc.
[{"type":"text","content":"DUBLIN, Aug. 28, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (\"Theravance Biopharma\" or the \"Company\") (NASDAQ: TBPH) today announced new ampreloxetine data in neurogenic orthostatic hypotension (nOH) will be presented at the 2023 International Congress of Parkinson's Disease and Movement Disorders (MDS), taking place August 27-31, 2023, in Copenhagen, Denmark.\n\n \n \n \n \n \n \n\n \n\"The data presented at this meeting continue to support ampreloxetine's potential to deliver a consistent and durable benefit to MSA patients with nOH with a favorable safety and tolerability profile,\" said Roy Freeman, MBChB, Professor of Neurology, Director, Center for Autonomic and Peripheral Nerve Disorders, Beth Israel Deaconess Medical Center. \"MSA is a rare, debilitating disease and many MSA patients suffer from symptoms related to poor blood pressure control that have a significant impact on their quality of life.\"1\nData will be presented in a poster session on Monday, August 28, 2023, starting at 1:00 PM Central European Time (7:00 AM EDT / 4:00 AM PDT / 11:00 AM GMT):\nCategory: Clinical Trials and Therapy in Movement Disorders (non-PD) (non-Dystonia)\nFreeman R, et al. Abstract 7 An Analysis of Subgroups of Multiple System Atrophy Patients from Ampreloxetine Phase 3 Trials\nBorin M, et al. Abstract 3 A Multiple-dose Thorough QT Study to Evaluate the Effect of Ampreloxetine on Cardiac Repolarization in Healthy Subjects\nFindings Presented at the 2023 MDS Congress:\nAmpreloxetine demonstrated the following benefits in MSA (multiple system atrophy) patients from studies 0169 [SEQUOIA] and 0170 [REDWOOD]:\nClinically-meaningful and nominally statistically significant (pPost-hoc analysis of Study 0170 indicated a consistent benefit of ampreloxetine relative to placebo across MSA subgroups including MSA sub-type (MSA-P and MSA-C), sex, age, time since MSA diagnosis, time since nOH onset, and the global MSA disability scale (UMSARS Part IV). Subgroup benefits of ampreloxetine ranged from 0.5 to 2.2 point improvements relative to placebo across all subgroup categories and were demonstrated on the OHSA and OHQ composite scores.Ampreloxetine was well-tolerated with similar adverse event rates compared to placebo during the placebo-controlled periods of both Study 0169 and Study 0170.In a separate single-center study evaluating ampre...